Pfizer Inc. Stock
€21.77
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug
3 Long-Term Dividend Buys You Can Get for Under $50
Despite ongoing concerns about overvalued stocks, many value investors sleep well at night. That’s because the key to long-term value investing is total return, which includes a healthy, growing
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Today’s stock market focus is centered on one single sector: technology stocks.
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
In a market where mega-cap growth and tech stocks continue to dominate headlines and stretch valuations, income-oriented investors may feel sidelined. But for those with a long-term perspective
This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)
The average blue chip dividend stock's current yield is somewhere in the ballpark of 3% to 4%. Therefore, to see one paying out nearly 7% of its value is as suspicious as it is impressive.
When the
Better Dividend Stock: Ford vs. Pfizer
Dividend stocks can be a good strategy for investors seeking a reliable and potentially more predictable stream of passive income. Two companies with high dividend yields are the longtime automaker
How Safe Is Pfizer's Dividend As 2026 Begins?
How many profitable, large-cap healthcare companies pay a dividend yield of over 5%? Only one.
Pfizer (NYSE: PFE) checks off all the boxes. It's profitable, raking in earnings of over $9.4 billion
2 Predictions for Pfizer in 2026
Is 2026 the year Pfizer (NYSE: PFE) finally turns things around? The company has been struggling over the past few years due to poor financial results and looming patent cliffs. However, it has also
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?
The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine
3 Drug Stocks to Buy at a Discount
The pharmaceutical industry is highly technical, and significant developments can rapidly transform the sector. For instance, Novo Nordisk's (NYSE: NVO) introduction of GLP-1 weight loss drugs was a
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often
Better Buy in 2026: Pfizer or Merck?
Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a
Better Buy in 2026: Pfizer or Eli Lilly?
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and growing their respective businesses for decades. But in recent years, it's been
If I Could Only Buy and Hold a Single Stock, This Would Be It
Stock investors have many options to choose among, of course. These include individual equities, exchange-traded funds (ETFs), and mutual funds. But if I had to pick just one stock, I'd invest in
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast
Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60%
Forget Teladoc and Buy This Healthcare Stock Instead
Telemedicine leader Teladoc Health (NYSE: TDOC) has been struggling for several years. The company's services are no longer experiencing the kind of demand they did during the pandemic years